Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology

Clinical and Translational Oncology

Volumn 17, Issue 10, 2015, Pages 763-771

  Goday, A ^a,b   Barneto, I ^c   Garcia Almeida J M ^d   Blasco, A ^e   Lecube, A ^f   Gravalos C ^g   Martinez de Icaya P ^h   de las Penas R ⁱ   Monereo, S ^j   Vazquez L ^k   Palacio, J E ^l   Perez Segura P ^m  

^a HOSPITAL DEL MAR   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL SEVERO OCHOA   (Spain)

ⁱ Servicio de Oncología Médica   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL MONTECELO   (Spain)

^l HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^m HOSPITAL CLÍNICO SAN CARLOS   (Spain)

more..

Author keywords

Adipokines; BMI; Fatty acids; IGF1 and 2; Inflammatory cytokines; Insulin

Indexed keywords

ADIPONECTIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLOOXYGENASE 2; ESTROGEN; FATTY ACID SYNTHASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; PROTEIN CDC42; SOMATOMEDIN B; SOMATOMEDIN C; STAT3 PROTEIN; TRANSCRIPTION FACTOR ETS 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ADIPOCYTOKINE; CYTOKINE; INSULIN;

ADIPOSE TISSUE; ARTICLE; BREAST CANCER; CENTRAL NERVOUS SYSTEM TUMOR; CHRONIC INFLAMMATION; CONSENSUS; DIGESTIVE SYSTEM CANCER; FEMALE GENITAL TRACT CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LUNG CANCER; MISMATCH REPAIR; NEOPLASM; OBESITY; ONCOLOGY; PROSTATE CANCER; RISK FACTOR; SPAIN; THYROID CANCER; TUMOR ASSOCIATED LEUKOCYTE; URINARY TRACT CANCER; WAIST CIRCUMFERENCE; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CONSENSUS DEVELOPMENT; ENDOMETRIAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; INFLAMMATION; KIDNEY NEOPLASMS; MALE; MEDICAL SOCIETY; METABOLISM; MORTALITY; NEOPLASMS; PANCREATIC NEOPLASMS; TUMOR RECURRENCE;

ADIPOKINES; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CYTOKINES; ENDOMETRIAL NEOPLASMS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; KIDNEY NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; OBESITY; PANCREATIC NEOPLASMS; RISK FACTORS; SOCIETIES, MEDICAL; SPAIN;

EID: 84941935477     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-015-1306-y     Document Type: Article

References (66)

1. WHO World Health Statistics. Geneva: World Health Organization; 2014. http://apps.who.int/iris/bitstream/10665/112738/1/9789240692671_eng.pdf
2. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–
3. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–81.
4. Recomendaciones nutricionales basadas en la evidencia para la prevención y el tratamiento del sobrepeso y la obesidad en adultos (Consenso FESNAD-SEEDO). Rev Esp Obes. 2011; 10 Suppl 1.http://www.seedo.es/images/site/documentacionConsenso/Guia_obesidad_SEEN_Endocrinologia_2003.pdf.
5. Berghöfer A, Pischon T, Reinhold T, Apovian CM, Sharma AM, Willich SN. Obesity prevalence from a European perspective: a systematic review. BMC Public Health. 2008;8:200.
6. González SCA, Goday AA. Obesidad y cáncer: “las amistades peligrosas”. Med Clin (Barc). 2014. Available at: http://dx.doi.org/10.1016/j.medcli.2014.05.026. Accessed Dec 2014.
7. Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. Lancet. 2014;384:755–65.
8. Ligibel JA, Alfano CM, Courneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, et al. American society of clinical oncology position statement on obesity and cancer. J Clin Oncol. 2014;32:3568–74.
9. Rubio Miguel A, Salas-Salvadó Jordi, Barbany Montserrat, Moreno Basilio, Aranceta Javier, Bellido D, et al. Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica (versión íntegra). Rev Esp Obes. 2007; 7–48. http://www.seedo.es/images/site/documentacionConsenso/Consenso_SEEDO_2007.pdf.
10. Garvey WT, Garber AJ, Mechanick JI, Bray GA, Dagogo-Jack S, Einhorn D, et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20:977–89.
11. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–14.
12. Gutierrez-Fisac JL, Guallar-Castillon P, Leon-Munoz LM, Graciani A, Banegas JR, Rodriguez-Artalejo F. Prevalence of general and abdominal obesity in the adult population of Spain, 2008-2010: the ENRICA study. Obes Rev. 2012;13:388–92.
13. Gomez-Ambrosi J, Silva C, Galofre JC, Escalada J, Santos S, Millan D, et al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond). 2012;36:286–94.
14. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211–9.
15. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11:886–95.
16. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med. 1993;177:1391–8.
17. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999;98:295–303.
18. Nkhata KJ, Ray A, Schuster TF, Grossmann ME, Cleary MP. Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep. 2009;21:1611–9.
19. Fusco R, Galgani M, Procaccini C, Franco R, Pirozzi G, Fucci L, et al. Cellular and molecular crosstalk between leptin receptor and estrogen receptor-{alpha} in breast cancer: molecular basis for a novel therapeutic setting. Endocr Relat Cancer. 2010;17:373–82.
20. Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 2004;4:604–16.
21. Zhang Y, Bellows CF, Kolonin MG. Adipose tissue-derived progenitor cells and cancer. World J Stem Cells. 2010;2:103–13.
22. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila). 2011;4:1021–9.
23. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222–5.
24. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550–62.
25. Kuhajda FP, Jenner K, Wood FD, Hennigar RA, Jacobs LB, Dick JD, et al. Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc Natl Acad Sci USA. 1994;91:6379–83.
26. Alli PM, Pinn ML, Jaffee EM, McFadden JM, Kuhajda FP. Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice. Oncogene. 2005;24:39–46.
27. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell. 2010;140:49–61.
28. Li YC, Park MJ, Ye SK, Kim CW, Kim YN. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am J Pathol. 2006;168:1107–18 quiz 404–5.
29. Tilg H, Moschen AR. Mechanisms behind the link between obesity and gastrointestinal cancers. Best Pract Res Clin Gastroenterol. 2014;28:599–610.
30. Shirakami Y, Shimizu M, Kubota M, Araki H, Tanaka T, Moriwaki H, et al. Chemoprevention of colorectal cancer by targeting obesity-related metabolic abnormalities. World J Gastroenterol. 2014;20:8939–46.
31. Lin XJ, Wang CP, Liu XD, Yan KK, Li S, Bao HH, et al. Body mass index and risk of gastric cancer: a meta-analysis. Jpn J Clin Oncol. 2014;44:783–91.
32. Kasenda B, Bass A, Koeberle D, Pestalozzi B, Borner M, Herrmann R, et al. Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. BMC Cancer. 2014;14:728.
33. Scarpa M, Ruffolo C, Erroi F, Fiorot A, Basato S, Pozza A, et al. Obesity is a risk factor for multifocal disease and recurrence after colorectal cancer surgery: a case-control study. Anticancer Res. 2014;34:5735–41.
34. Meyerhardt JA, Catalano PJ, Haller DG, Mayer RJ, Benson AB 3rd, Macdonald JS, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484–95.
35. Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, et al. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials. J Clin Oncol. 2012;30:406–12.
36. Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134.
37. Doll KM, Kalinowski AK, Snavely AC, Irwin DE, Bensen JT, Bae-Jump VL, et al. Obesity is associated with worse quality of life in women with gynecologic malignancies: an opportunity to improve patient-centered outcomes. Cancer. 2015;121:395–402. doi:10.1002/cncr.29061.
38. Dossus L, Rinaldi S, Becker S, Lukanova A, Tjonneland A, Olsen A, et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer. 2010;17:1007–19.
39. Lahmann PH, Cust AE, Friedenreich CM, Schulz M, Lukanova A, Kaaks R, et al. Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;126:2404–15.
40. Schouten LJ, Rivera C, Hunter DJ, Spiegelman D, Adami HO, Arslan A, et al. Height, body mass index, and ovarian cancer: a pooled analysis of 12 cohort studies. Cancer Epidemiol Biomarkers Prev. 2008;17:902–12.
41. Martin-Ramiro JJ, Alvarez-Martin E, Gil-Prieto R. Mortality attributable to excess weight in Spain. Med Clin (Barc). 2014;142:526–30.
42. Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25:1901–14.
43. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer—mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol. 2014;10:455–65.
44. Goodwin PJ, Ennis M, Fantus IG, Pritchard KI, Trudeau ME, Koo J, et al. Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol. 2005;23:6037–42.
45. Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press). 2014;6:59–71.
46. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.
47. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.
48. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med. 2000;343:1305–11.
49. Zigeuner R. Editorial comment on: lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear-cell carcinoma of the kidney. Eur Urol. 2008;54:873–4.
50. Buschemeyer WC 3rd, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007;52:331–43.
51. Mistry T, Digby JE, Desai KM, Randeva HS. Obesity and prostate cancer: a role for adipokines. Eur Urol. 2007;52:46–53.
52. Ribeiro R, Monteiro C, Catalan V, Hu P, Cunha V, Rodriguez A, et al. Obesity and prostate cancer: gene expression signature of human periprostatic adipose tissue. BMC Med. 2012;10:108.
53. Pruthi RS, Swords K, Schultz H, Carson CC 3rd, Wallen EM. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. J Urol. 2009;181:574–7 discussion 8.
54. Motamedinia P, Korets R, Spencer BA, Benson MC, McKiernan JM. Body mass index trends and role of obesity in predicting outcome after radical prostatectomy. Urology. 2008;72:1106–10.
55. Koebnick C, Michaud D, Moore SC, Park Y, Hollenbeck A, Ballard-Barbash R, et al. Body mass index, physical activity, and bladder cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2008;17:1214–21.
56. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol. 2003;169:714–7.
57. Hilmy M, Bartlett JM, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer. 2005;92:625–7.
58. Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer. 2013;132:1162–9.
59. Zhao ZG, Guo XG, Ba CX, Wang W, Yang YY, Wang J, et al. Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J Int Med Res. 2012;40:2041–50.
60. Larsson SC, Wolk A. Obesity and risk of non-Hodgkin’s lymphoma: a meta-analysis. Int J Cancer. 2007;121:1564–70.
61. Wiedmann M, Brunborg C, Lindemann K, Johannesen TB, Vatten L, Helseth E, et al. Body mass index and the risk of meningioma, glioma and schwannoma in a large prospective cohort study (The HUNT Study). Br J Cancer. 2013;109:289–94.
62. Khan N, Afaq F, Mukhtar H. Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett. 2010;293:133–43.
63. Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI, et al. Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1803–11.
64. Thygesen LC, Gronbaek M, Johansen C, Fuchs CS, Willett WC, Giovannucci E. Prospective weight change and colon cancer risk in male US health professionals. Int J Cancer. 2008;123:1160–5.
65. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104:815–40.
66. Goodwin PJ, Segal RJ, Vallis M, Ligibel JA, Pond GR, Robidoux A, et al. Randomized trial of a telephone-based weight loss intervention in postmenopausal women with breast cancer receiving letrozole: the LISA trial. J Clin Oncol. 2014;32:2231–9.